Cargando…
Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy
Peripartum cardiomyopathy (PPCM) is a poorly understood, rare disorder in which left ventricular systolic dysfunction and symptoms of heart failure occur between the last month of pregnancy and the first 5 months postpartum. Recent data suggest that uncontrolled oxidative stress leads to the activat...
Autores principales: | Chopra, Sandeep, Verghese, Prashant Paul, Jacob, Jubbin J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3354950/ https://www.ncbi.nlm.nih.gov/pubmed/22701847 http://dx.doi.org/10.4103/2230-8210.94261 |
Ejemplares similares
-
Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases
por: Simon, Rebecca, et al.
Publicado: (2018) -
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study
por: Hilfiker-Kleiner, Denise, et al.
Publicado: (2017) -
A Systematic Review of the Utility of Bromocriptine in Acute Peripartum Cardiomyopathy
por: Badianyama, Marheb, et al.
Publicado: (2021) -
Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction
por: Haghikia, Arash, et al.
Publicado: (2018) -
Peripartum Cardiomyopathy Presenting with Predominant Left Ventricular Diastolic Dysfunction: Efficacy of Bromocriptine
por: Ballo, Piercarlo, et al.
Publicado: (2012)